Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2013

Open Access 01-12-2013 | Study protocol

The clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial

Authors: Elisabeth G Klompenhouwer, Paul D Gobardhan, Martinus A Beek, Adri C Voogd, Ernest JT Luiten

Published in: Trials | Issue 1/2013

Login to get access

Abstract

Background

Axillary lymph node dissection (ALND) in patients with breast cancer has the potential to induce side-effects, including upper-limb lymphedema. Axillary reverse mapping (ARM) is a technique that enables discrimination of the lymphatic drainage of the breast from that of the upper limb in the axillary lymph node (LN) basin. If lymphedema is caused by removing these lymphatics and nodes in the upper limb, the possibility of identifying these lymphatics would enable surgeons to preserve them. The aim of this study is to determine the clinical relevance of selective axillary LN and lymphatic preservation by means of ARM. To minimize the risk of overlooking tumor-positive ARM nodes and the associated risk of undertreatment, we will only include patients with a tumor-positive sentinel lymph node (SLN). Patients who are candidates for ALND because of a proven positive axillary LN at clinical examination can be included in a registration study.

Methods/design

The study will enroll 280 patients diagnosed with SLN biopsy-proven metastasis of invasive breast cancer with an indication for a completion ALND. Patients will be randomized to undergo standard ALND or an ALND in which the ARM nodes and their corresponding lymphatics will be left in situ. Primary outcome is the presence of axillary surgery-related lymphedema at 6, 12, and 24 months post-operatively, measured by the water-displacement method. Secondary outcome measures include pain, paresthesia, numbness, and loss of shoulder mobility, quality of life, and axillary recurrence risk.

Discussion

The benefit of ALND in patients with a positive SLN is a subject of debate. For many patients, an ALND will remain the treatment of choice. This multicenter randomized trial will provide evidence of whether or not axillary LN preservation by means of ARM decreases the side-effects of an ALND. Enrolment of patients will start in April 2013 in five breast-cancer centers in the Netherlands, and is expected to conclude by April 2016.

Trial registration

TC3698
Appendix
Available only for authorised users
Literature
1.
Hack TF, Cohen L, Katz J, Robson LS, Goss P: Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol. 1999, 17 (1): 143-149.PubMed
2.
Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME: Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol. 2003, 29 (4): 341-350. 10.1053/ejso.2002.1385.CrossRefPubMed
3.
Ronka R, von Smitten K, Tasmuth T, Leidenius M: One-year morbidity after sentinel node biopsy and breast surgery. Breast. 2005, 14 (1): 28-36. 10.1016/j.breast.2004.09.010.CrossRefPubMed
4.
Klimberg VS: A new concept toward the prevention of lymphoedema: axillary reverse mapping. J Surg Oncol. 2008, 97 (7): 563-564. 10.1002/jso.20905.CrossRefPubMed
5.
Ponzone R, Mininanni P, Cassina E, Sismondi P: Axillary reverse mapping in breast cancer: can we spare what we find?. Ann Surg Oncol. 2008, 15 (1): 390-391. 10.1245/s10434-007-9663-6. author reply 2–3CrossRefPubMed
6.
Nos C, Lesieur B, Clough KB, Lecuru F: Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol. 2007, 14 (9): 2490-2496. 10.1245/s10434-007-9450-4.CrossRefPubMed
7.
Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook KC: Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol. 2007, 14 (6): 1890-1895. 10.1245/s10434-007-9412-x.CrossRefPubMed
8.
Boneti C, Korourian S, Bland K, Cox K, Adkins LL, Henry-Tillman RS: Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphoedema during sentinel lymph node biopsy. J Am Coll Surg. 2008, 206 (5): 1038-1042. 10.1016/j.jamcollsurg.2007.12.022. discussion 42–4CrossRefPubMed
9.
Casabona F, Bogliolo S, Ferrero S, Boccardo F, Campisi C: Axillary reverse mapping in breast cancer: a new microsurgical lymphatic-venous procedure in the prevention of arm lymphoedema. Ann Surg Oncol. 2008, 15 (11): 3318-3319. 10.1245/s10434-008-0118-5.CrossRefPubMed
10.
Casabona F, Bogliolo S, Valenzano Menada M, Sala P, Villa G, Ferrero S: Feasibility of axillary reverse mapping during sentinel lymph node biopsy in breast cancer patients. Ann Surg Oncol. 2009, 16 (9): 2459-2463. 10.1245/s10434-009-0554-x.CrossRefPubMed
11.
Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P: Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol. 2008, 15 (9): 2550-2555. 10.1245/s10434-008-0030-z.CrossRefPubMed
12.
Noguchi M, Yokoi M, Nakano Y: Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer. J Surg Oncol. 2010, 101 (3): 217-221.PubMed
13.
Britton TB, Solanki CK, Pinder SE, Mortimer PS, Peters AM, Purushotham AD: Lymphatic drainage pathways of the breast and the upper limb. Nucl Med Commun. 2009, 30 (6): 427-430. 10.1097/MNM.0b013e328315a6c6.CrossRefPubMed
14.
Noguchi M: Axillary reverse mapping for breast cancer. Breast Cancer Res Treat. 2010, 119 (3): 529-10.1007/s10549-009-0578-8.CrossRefPubMed
15.
Gobardhan PD, Wijsman JH, van Dalen T, Klompenhouwer EG, van der Schelling GP, Los J, Voogd AC, Luiten EJ: ARM: axillary reverse mapping - the need for selection of patients. Eur J Surg Oncol. 2012, 38 (8): 657-661. 10.1016/j.ejso.2012.04.012.CrossRefPubMed
16.
Boneti C, Badgwell B, Roberton Y, Korourian S, Adkins L, Klimberg V: Axillary reverse mapping (ARM): initial results of phase II trial in preventing lymphedema after lymphadenectomy. Minerva ginecol. 2012, 64: 421-430.PubMed
17.
Damstra RJ, Glazenbrug EJ, Hop WCJ: Validation of the inverse water volumetry method: a new gold standard for arm volume measurements. Breast cancer res treat. 2006, 99: 267-273. 10.1007/s10549-006-9213-0.CrossRefPubMed
18.
Lopez Penha TR, Slangen JJ, Heuts EM, Voogd AC, Von Meyenfeldt MF: Prevalence of lymphoedema more than five years after breast cancer treatment. Eur J Surg Oncol. 2011, 37 (12): 1059-1063. 10.1016/j.ejso.2011.09.001.CrossRefPubMed
19.
Ververs JM, Roumen RM, Vingerhoets AJ, Vreugdenhil G, Coebergh JW, Crommelin MA: Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001, 37 (8): 991-999. 10.1016/S0959-8049(01)00067-3.CrossRefPubMed
20.
Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006, 106 (1): 4-16. 10.1002/cncr.21568.CrossRefPubMed
21.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J: Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol. 2010, 28 (5): 731-737. 10.1200/JCO.2008.21.7554.CrossRefPubMed
22.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002, 347 (8): 567-575. 10.1056/NEJMoa020128.CrossRefPubMed
23.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW: Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011, 305 (6): 569-575. 10.1001/jama.2011.90.CrossRefPubMed
24.
Avril A, Le Bouedec G, Lorimier G, Classe JM, Tunon-de-Lara C, Giard S: Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up. Eur J Surg Oncol. 2011, 37 (7): 563-570. 10.1016/j.ejso.2011.04.008.CrossRefPubMed
25.
Fisher B, Wolmark N, Fisher ER, Deutsch M: Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations. World J Surg. 1985, 9 (5): 692-698. 10.1007/BF01655182.CrossRefPubMed
26.
Deutsch M, Land S, Begovic M, Sharif S: The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008, 70 (4): 1020-1024. 10.1016/j.ijrobp.2007.07.2376.CrossRefPubMed
27.
Sakorafas GH, Peros G, Cataliotti L, Vlastos G: Lymphoedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006, 15 (3): 153-165. 10.1016/j.suronc.2006.11.003.CrossRefPubMed
28.
Metadata
Title
The clinical relevance of axillary reverse mapping (ARM): study protocol for a randomized controlled trial
Authors
Elisabeth G Klompenhouwer
Paul D Gobardhan
Martinus A Beek
Adri C Voogd
Ernest JT Luiten
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Trials / Issue 1/2013
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-14-111

Other articles of this Issue 1/2013

Trials 1/2013 Go to the issue

Study protocol

Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial

Study protocol

Rationale and study design of ViPS – variable pressure support for weaning from mechanical ventilation: study protocol for an international multicenter randomized controlled open trial

Study protocol

Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial

Study protocol

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial

Study protocol

Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids

Study protocol

TRialing individualized interventions to prevent functional decline in at-risk older adults (TRIIFL): study protocol for a randomized controlled trial nested in a longitudinal observational study